A molecular tweezers that is capable of inhibiting protein aggregation for use in the treatment of a lysosomal storage disease in a mammal; wherein said lysosomal storage disease comprises a pathology selected from the group consisting of a mucopolysaccharidosis, aspartylglucosaminuria, GM1-gangliosidosis, Krabbe (globoid cell leukodystrophy or galactosylceramide lipidosis), Metachromatic leukodystrophy, Sandhoff disease, mucolipidosis type II (I-cell disease), mucolipidosis type IIIA (pseudo-Hurler polydystrophy), Niemann-Pick disease type C2 and C1, Danon disease, free sialic acid storage disorder, mucolipidosis type IV, and multiple sulfatase deficiency; and wherein said molecular tweezers is a molecular tweezers according to any one of formulas I to IV: and or a pharmaceutically acceptable salt, ester or amide thereof, wherein: X 1 and X 2 are both O; A alone, or A combined with X 1, forms a substituent selected from the group consisting of phosphate, hydrogen phosphate, alkylphosphonate, arylphosphonate, alkylphosphamide, arylphosphamide, sulfate, hydrogen sulfate, alkylcarboxylate, and B alone, or B combined with X 2, forms a substituent selected from the group consisting of phosphate, hydrogen phosphate, alkylphosphonate, arylphosphonate, alkylphosphamide, arylphosphamide, sulfate, hydrogen sulfate, alkylcarboxylate and and each of R 1, R 2, R 3, and R 4 is, independently, selected from the group consisting of H, Cl, Br, I, OR, NR 2, NO 2, CO 2 H, and CO 2 R 5, wherein R 5 is alkyl, aryl or H, or R 1 and R 2 combine to form an aliphatic or aromatic ring, and/or R 3 and R 4 combine to form an aliphatic or aromatic ring. wherein said lysosomal storage disease comprises a pathology selected from the group consisting of a mucopolysaccharidosis, aspartylglucosaminuria, GM1-gangliosidosis, Krabbe (globoid cell leukodystrophy or galactosylceramide lipidosis), Metachromatic leukodystrophy, Sandhoff disease, mucolipidosis type II (I-cell disease), mucolipidosis type IIIA (pseudo-Hurler polydystrophy), Niemann-Pick disease type C2 and C1, Danon disease, free sialic acid storage disorder, mucolipidosis type IV, and multiple sulfatase deficiency; and wherein said molecular tweezers is a molecular tweezers according to any one of formulas I to IV: and or a pharmaceutically acceptable salt, ester or amide thereof, wherein: X 1 and X 2 are both O; A alone, or A combined with X 1, forms a substituent selected from the group consisting of phosphate, hydrogen phosphate, alkylphosphonate, arylphosphonate, alkylphosphamide, arylphosphamide, sulfate, hydrogen sulfate, alkylcarboxylate, and B alone, or B combined with X 2, forms a substituent selected from the group consisting of phosphate, hydrogen phosphate, alkylphosphonate, arylphosphonate, alkylphosphamide, arylphosphamide, sulfate, hydrogen sulfate, alkylcarboxylate and and each of R 1, R 2, R 3, and R 4 is, independently, selected from the group consisting of H, Cl, Br, I, OR, NR 2, NO 2, CO 2 H, and CO 2 R 5, wherein R 5 is alkyl, aryl or H, or R 1 and R 2 combine to form an aliphatic or aromatic ring, and/or R 3 and R 4 combine to form an aliphatic or aromatic ring. X 1 and X 2 are both O; A alone, or A combined with X 1, forms a substituent selected from the group consisting of phosphate, hydrogen phosphate, alkylphosphonate, arylphosphonate, alkylphosphamide, arylphosphamide, sulfate, hydrogen sulfate, alkylcarboxylate, and B alone, or B combined with X 2, forms a substituent selected from the group consisting of phosphate, hydrogen phosphate, alkylphosphonate, arylphosphonate, alkylphosphamide, arylphosphamide, sulfate, hydrogen sulfate, alkylcarboxylate and and each of R 1, R 2, R 3, and R 4 is, independently, selected from the group consisting of H, Cl, Br, I, OR, NR 2, NO 2, CO 2 H, and CO 2 R 5, wherein R 5 is alkyl, aryl or H, or R 1 and R 2 combine to form an aliphatic or aromatic ring, and/or R 3 and R 4 combine to form an aliphatic or aromatic ring.